Castle Biosciences, Inc.

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

The Company’s innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. Castle currently markets five proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, Barrett’s esophagus, and uveal melanoma.

DecisionDx®-Melanoma, Castle’s test for invasive cutaneous melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors.

DecisionDx®-SCC is the Company’s GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors.

MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions.

TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus.

DecisionDx®-UM, the standard of care in uveal melanoma staging, is Castle's GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer.

Castle Biosciences is based in Friendswood, TX, (a suburb of Houston) and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.